We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A 30,000-sq. ft cGMP facility and a separate R&D site will work alongside each other to provide end-to end product development solutions for Singapore and low- and middle-income countries
Hilleman Laboratories, a joint-venture partnership between MSD and Wellcome Trust, received a six million krona Indo – Swedish grant for the project, ‘Improved, affordable single strain whole cell-B subunit oral cholera vaccine’.